Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus VEETIDS 500.
OMNIPEN-N vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic